Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (TSE:ONC)
:ONC
ONC Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Oncolytics Biotech News
ONC FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Currently, no data Available
What is Oncolytics Biotech’s market cap?
Currently, no data Available
When is Oncolytics Biotech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Oncolytics Biotech’s earnings last quarter?
Currently, no data Available
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncolytics Biotech have?
Currently, no data Available
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in TSE:ONC
Company Description
Oncolytics Biotech
Oncolytics Biotech Inc. is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. Operating primarily in the biopharmaceutical sector, the company is committed to advancing its proprietary oncology platform, which includes its lead product candidate, pelareorep. Pelareorep is an intravenously delivered immuno-oncolytic virus designed to selectively target and destroy cancer cells while stimulating the immune system's anti-tumor response. Oncolytics Biotech aims to enhance the effectiveness of a broad range of cancer treatments through strategic collaborations and cutting-edge research.